Ovintiv Inc.
OVVOvintiv Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +54.1% in a year while annual EPS moved +13.5% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (23 weeks in). Underneath, the last four quarters read improving, and 259% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Ovintiv Inc. trades at $60.8, in a confirmed uptrend and 23 weeks into that stage. That is +22.4% against its own 200-day average. It sits at 91% of a 52-week range of $36 to $63. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 23 of stage 2. At $60.8 it trades +22.4% versus its 200-day average and sits at 91% of its 52-week range ($36–$63).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +59% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Ovintiv Inc. trades at 17.6× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 17.6× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +13.5% against a +54.1% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +8.2%/yr price move, ~−38.4%/yr came from earnings growth and ~+46.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Ovintiv Inc. reads as turning around on its fundamental arc. Turning around — profit growth swung from −69.2% at the trough to +23.8%, a 2-quarter improving streak, ROCE holding at 12.2%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −3.1% | −15.3% | — | — |
| Profit | +9.7% | −30.2% | — | — |
| EPS | +13.5% | −30.2% | — | — |
| Stock price | +54.1% | +8.2% | +19.0% | +3.8% |
4-Factor Sector Score
65.0/100 — rank 2 of 30 in Oil & Gas Exploration & Production · 58% evidence confidence
Ovintiv Inc. scores 65.0 out of 100 against the 30 companies it is compared with in Oil & Gas Exploration & Production, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 20.9 + 16.7 + 9.4 + 18 = 65. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Ovintiv Inc. reported $2.6 B of revenue in the Mar 26 quarter, +8.4% year on year. Over 4 years it has compounded at −4.6% a year. The last full year, FY25, came in at $8.7 B. The last four reported quarters add to $8.9 B.
FY25 revenue came in at $8.7 B (−3.1% on the year), capping 4 years at −4.6% compound. The latest quarter (Mar 26) printed $2.6 B, +8.4% year on year.
Pace check: the last four quarters averaged −1.1% growth against the decade's −4.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.9% over the last 4 quarters against −7.9%/yr over the last 8 — accelerating; TTM profit +23.8% vs −36.8%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Ovintiv Inc.'s operating margin is 29.1% in the Mar 26 quarter, +1.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.6% to 27.1%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 29.1%, +1.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.6%–27.1%.
Why the margin moved: operating margin went +1.8 pp year on year while gross margin went +2.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Ovintiv Inc. posted a net loss of $0.6 B in the Mar 26 quarter. Full-year FY25 profit was $1.2 B. The 4-year compound rate is −3.3%. That loss is 24.4% of the quarter's revenue. The same quarter a year earlier lost $0.2 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.6 B, null year on year. On the full year, FY25 printed $1.2 B (+9.7%), and the 4-year compound rate is −3.3%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 259% of Ovintiv Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.6 B of operating cash against $1.2 B of profit. After $4.7 B of capital spending, $−1.0 B was left as free cash.
FY25: operating cash of $3.6 B against reported profit of $1.2 B, leaving free cash of $−1.0 B after $4.7 B of capital spending. Across the last 3 fiscal years the conversion rate is 259% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Ovintiv Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $10.0 B over the last 3 years. Averaged over those years that is 38.5% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $10.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Ovintiv Inc. earns a ROE of 11% in FY25. That is up from a trough of 11% in FY24. Return on invested capital clears the cost of that capital by +8.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.3% net margin on 0.42× asset turns.
FY25 ROE is 11%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 14.3% net margin × 0.42× asset turns × 1.82× balance-sheet leverage ≈ 10.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 15.3% − 7.0% = a +8.3 pp spread. The 7.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Ovintiv Inc. paid $1.20 per share over the last four reported quarters, up 20.0% on a year ago. The most recent declaration was $0.30 for Mar 26. Against the current price of $60.8 that is a trailing yield of 1.98%, measured on dividends already paid rather than on a forecast.
Ovintiv Inc. paid $1.20 per share across the last four reported quarters, most recently $0.30 for Mar 26. That is up 20.0% against the same quarter a year earlier. Against the current price of $60.8 the trailing twelve months work out to 1.98% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Ovintiv Inc. carries total debt of $5.0 B against shareholder equity of $11.5 B as of Jun 26, a debt-to-equity of 0.44. On the annual view that ratio went from 1.14 in FY21 to 0.57 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $5.0 B against shareholder equity of $11.5 B — a debt-to-equity of 0.44. On the annual view, debt-to-equity went from 1.14 (FY21) to 0.57 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.2% of Ovintiv Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.2% of the float is sold short, and at typical trading volumes it would take about 4.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Ovintiv Inc.: the Z-score reads 2.06. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.06 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.06.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1APA CorporationAPA | 65.8/100Favorable setup81% evidence | ASLEEP | 23.0/35 Revenue -17.4% · PAT 37.2% · OPM change 15.2 pp 83% evidence | 15.1/25 ROCE 6.4% · OPM 42.9% 76% evidence | 14.9/20 P/E 9.9× · PEG 0.18 65% evidence | 12.8/20 RS sector 10.9% · RS bench 7.5% · 1Y 78.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23 + 15.1 + 14.9 + 12.8 = 65.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Ovintiv Inc.this pageOVV | 65.0/100Thin evidence · provisional58% evidence | TURNING | 20.9/35 Revenue — · PAT — · OPM change 1.8 pp 45% evidence | 16.7/25 ROCE 15.8% · OPM 29.2% 76% evidence | 9.4/20 P/E 16.1× · PEG — 15% evidence | 18.0/20 RS sector 16.6% · RS bench 13.6% · 1Y 52.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 16.7 + 9.4 + 18 = 65 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Canadian Natural Resources LimitedCNQ | 59.3/100Mixed-positive evidence81% evidence | ASLEEP | 18.0/35 Revenue 0.7% · PAT 28.1% · OPM change -5.4 pp 83% evidence | 14.0/25 ROCE 3.3% · OPM 24.7% 76% evidence | 11.6/20 P/E 14.6× · PEG 0.49 65% evidence | 15.7/20 RS sector 9.7% · RS bench 6.8% · 1Y 52.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 14 + 11.6 + 15.7 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Black Stone Minerals, L.P.BSM | 58.9/100Mixed-positive evidence81% evidence | TURNING | 23.7/35 Revenue 20.9% · PAT 33.2% · OPM change -1 pp 83% evidence | 11.3/25 ROCE 1.3% · OPM 28% 76% evidence | 13.8/20 P/E 11.9× · PEG 0.31 65% evidence | 10.1/20 RS sector -3.1% · RS bench -4.6% · 1Y 21.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 11.3 + 13.8 + 10.1 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Vista Energy, S.A.B. de C.V.VIST | 56.8/100Thin evidence · provisional58% evidence | ASLEEP | 15.5/35 Revenue — · PAT — · OPM change -7.5 pp 45% evidence | 16.0/25 ROCE 8.9% · OPM 24.9% 76% evidence | 11.1/20 P/E 8.4× · PEG — 15% evidence | 14.2/20 RS sector 9.9% · RS bench 6.6% · 1Y 55.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 16 + 11.1 + 14.2 = 56.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Permian Resources CorporationPR | 56.4/100Mixed-positive evidence81% evidence | ASLEEP | 14.2/35 Revenue -1.1% · PAT -46.3% · OPM change -2.9 pp 83% evidence | 13.7/25 ROCE 2.9% · OPM 33.7% 76% evidence | 11.5/20 P/E 24.8× · PEG 0.38 65% evidence | 17.0/20 RS sector 12.9% · RS bench 9.8% · 1Y 54.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 13.7 + 11.5 + 17 = 56.4 · Decision use: Price leads the evidence: RS versus the benchmark is 9.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7EOG Resources, Inc.EOG | 54.4/100Thin evidence · provisional58% evidence | TURNING | 16.9/35 Revenue — · PAT — · OPM change 4.7 pp 45% evidence | 10.8/25 ROCE 0% · OPM 37.5% 76% evidence | 9.7/20 P/E 14.2× · PEG — 15% evidence | 17.0/20 RS sector 6.9% · RS bench 4.8% · 1Y 23.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 10.8 + 9.7 + 17 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Texas Pacific Land CorporationTPL | 54.1/100Mixed-positive evidence81% evidence | ASLEEP | 21.6/35 Revenue 15.4% · PAT 9.1% · OPM change 0.4 pp 83% evidence | 18.7/25 ROCE 12.5% · OPM 77% 76% evidence | 3.9/20 P/E 65× · PEG 6.88 65% evidence | 9.9/20 RS sector -1.7% · RS bench -4.4% · 1Y 37.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 18.7 + 3.9 + 9.9 = 54.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Gulfport Energy CorporationGPOR | 53.0/100Mixed-positive evidence64% evidence | BASING | 25.5/35 Revenue 90.8% · PAT — · OPM change 45.9 pp 62% evidence | 14.1/25 ROCE 8.9% · OPM 52% 76% evidence | 11.4/20 P/E 7.2× · PEG — 15% evidence | 2.0/20 RS sector -24.3% · RS bench -25.4% · 1Y -6.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.5 + 14.1 + 11.4 + 2 = 53 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -24.3% and the one-year return is -6.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 10Antero Resources CorporationAR | 52.6/100Thin evidence · provisional58% evidence | BASING | 21.2/35 Revenue — · PAT — · OPM change 17.4 pp 45% evidence | 12.3/25 ROCE 3% · OPM 37.5% 76% evidence | 10.8/20 P/E 10.1× · PEG — 15% evidence | 8.3/20 RS sector -7.2% · RS bench -9% · 1Y 8.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 10.8 + 8.3 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Baytex Energy Corp.BTE | 52.5/100Thin evidence · provisional53% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change -10.5 pp 32% evidence | 11.4/25 ROCE 4.3% · OPM 12.8% 76% evidence | 10.4/20 P/E 11.6× · PEG — 15% evidence | 12.7/20 RS sector 11.2% · RS bench 7.9% · 1Y 106.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.4 + 10.4 + 12.7 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Range Resources CorporationRRC | 51.8/100Thin evidence · provisional58% evidence | BASING | 20.7/35 Revenue — · PAT — · OPM change 11.9 pp 45% evidence | 12.6/25 ROCE 2.8% · OPM 46.7% 76% evidence | 10.7/20 P/E 10.3× · PEG — 15% evidence | 7.8/20 RS sector -5.3% · RS bench -7.1% · 1Y 14.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 12.6 + 10.7 + 7.8 = 51.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Crescent Energy CompanyCRGY | 50.3/100Mixed-positive evidence64% evidence | ASLEEP | 21.7/35 Revenue 18.3% · PAT — · OPM change 9.6 pp 62% evidence | 11.4/25 ROCE 3.4% · OPM 27.7% 76% evidence | 9.5/20 P/E 15.5× · PEG — 15% evidence | 7.7/20 RS sector 0.9% · RS bench -1.8% · 1Y 22.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 11.4 + 9.5 + 7.7 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14SM Energy CompanySM | 50.2/100Mixed-positive evidence81% evidence | TURNING | 11.7/35 Revenue 27.3% · PAT -84% · OPM change -52.8 pp 83% evidence | 6.3/25 ROCE -2.6% · OPM -20.1% 76% evidence | 13.0/20 P/E 13.1× · PEG 0.35 65% evidence | 19.2/20 RS sector 12.5% · RS bench 10.1% · 1Y 18.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 6.3 + 13 + 19.2 = 50.2 · Decision use: Price leads the evidence: RS versus the benchmark is 10.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15BKV CorporationBKV | 48.4/100Mixed-negative evidence64% evidence | ASLEEP | 26.0/35 Revenue 100% · PAT — · OPM change 76.8 pp 62% evidence | 10.6/25 ROCE 3% · OPM 19.9% 76% evidence | 11.0/20 P/E 8.6× · PEG — 15% evidence | 0.8/20 RS sector -19% · RS bench -20.6% · 1Y 16.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26 + 10.6 + 11 + 0.8 = 48.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -19% and the one-year return is 16.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 16CNX Resources CorporationCNX | 48.0/100Thin evidence · provisional58% evidence | ASLEEP | 16.4/35 Revenue — · PAT — · OPM change 347.8 pp 45% evidence | 13.1/25 ROCE 3.4% · OPM 60.4% 76% evidence | 11.5/20 P/E 5.7× · PEG — 15% evidence | 7.0/20 RS sector -8.8% · RS bench -10.4% · 1Y 22.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 13.1 + 11.5 + 7 = 48 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Chord Energy CorporationCHRD | 47.7/100Mixed-negative evidence71% evidence | ASLEEP | 11.3/35 Revenue -1% · PAT -89.1% · OPM change -7.8 pp 83% evidence | 11.8/25 ROCE 2.9% · OPM 20% 76% evidence | 8.6/20 P/E 125.3× · PEG — 15% evidence | 16.0/20 RS sector 11.8% · RS bench 9.1% · 1Y 35.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 11.8 + 8.6 + 16 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 9.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18ConocoPhillipsCOP | 47.2/100Thin evidence · provisional58% evidence | ASLEEP | 15.1/35 Revenue — · PAT — · OPM change -4.2 pp 45% evidence | 9.8/25 ROCE 0% · OPM 20.7% 76% evidence | 9.1/20 P/E 23.9× · PEG — 15% evidence | 13.2/20 RS sector 2.6% · RS bench 0.3% · 1Y 25.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 9.8 + 9.1 + 13.2 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Magnolia Oil & Gas CorporationMGY | 46.8/100Mixed-negative evidence81% evidence | BASING | 14.8/35 Revenue -1.9% · PAT -18.7% · OPM change -3.2 pp 83% evidence | 15.7/25 ROCE 4.9% · OPM 35.6% 76% evidence | 14.0/20 P/E 18.4× · PEG 0.1 65% evidence | 2.3/20 RS sector -12.3% · RS bench -14.1% · 1Y 4.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 15.7 + 14 + 2.3 = 46.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20Occidental Petroleum CorporationOXY | 45.3/100Thin evidence · provisional58% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -10.5 pp 45% evidence | 7.7/25 ROCE 0% · OPM 13.4% 76% evidence | 10.1/20 P/E 13× · PEG — 15% evidence | 13.0/20 RS sector 2.3% · RS bench -0.1% · 1Y 24.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 7.7 + 10.1 + 13 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Murphy Oil CorporationMUR | 45.1/100Mixed-negative evidence71% evidence | ASLEEP | 12.9/35 Revenue -5.1% · PAT -74.8% · OPM change -2.5 pp 83% evidence | 10.3/25 ROCE 1.6% · OPM 18.9% 76% evidence | 8.7/20 P/E 69.9× · PEG — 15% evidence | 13.2/20 RS sector 6.2% · RS bench 3.8% · 1Y 64.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 10.3 + 8.7 + 13.2 = 45.1 · Decision use: Price leads the evidence: RS versus the benchmark is 3.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Expand Energy CorporationEXE | 44.7/100Thin evidence · provisional58% evidence | BASING | 16.5/35 Revenue — · PAT — · OPM change 47 pp 45% evidence | 10.7/25 ROCE 2.6% · OPM 34.8% 76% evidence | 11.3/20 P/E 7.9× · PEG — 15% evidence | 6.2/20 RS sector -17.4% · RS bench -18.3% · 1Y -6.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 10.7 + 11.3 + 6.2 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Diamondback Energy, Inc.FANG | 44.6/100Mixed-negative evidence81% evidence | ASLEEP | 10.8/35 Revenue 18.1% · PAT -95.4% · OPM change -38.6 pp 83% evidence | 7.7/25 ROCE 0.2% · OPM 2.7% 76% evidence | 13.3/20 P/E 230× · PEG 0.1 65% evidence | 12.8/20 RS sector 4.7% · RS bench 2.4% · 1Y 35.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.8 + 7.7 + 13.3 + 12.8 = 44.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24EQT CorporationEQT | 43.0/100Thin evidence · provisional58% evidence | BASING | 17.4/35 Revenue — · PAT — · OPM change 31.8 pp 45% evidence | 10.6/25 ROCE 1% · OPM 60.3% 76% evidence | 10.2/20 P/E 12.3× · PEG — 15% evidence | 4.8/20 RS sector -13.7% · RS bench -15.1% · 1Y 2.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 10.6 + 10.2 + 4.8 = 43 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Comstock Resources, Inc.CRK | 42.4/100Thin evidence · provisional58% evidence | BASING | 17.6/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence | 8.0/25 ROCE 0.4% · OPM 29.8% 76% evidence | 11.2/20 P/E 8.4× · PEG — 15% evidence | 5.6/20 RS sector -35.4% · RS bench -36.1% · 1Y -16.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 8 + 11.2 + 5.6 = 42.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Devon Energy CorporationDVN | 39.2/100Mixed-negative evidence71% evidence | ASLEEP | 12.3/35 Revenue -1.5% · PAT -19.4% · OPM change -9.8 pp 83% evidence | 9.8/25 ROCE 1.1% · OPM 7.7% 76% evidence | 9.8/20 P/E 14× · PEG — 15% evidence | 7.3/20 RS sector -0.3% · RS bench -2.7% · 1Y 32.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 9.8 + 9.8 + 7.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Talos Energy Inc.TALO | 35.0/100Thin evidence · provisional56% evidence | ASLEEP | 12.1/35 Revenue — · PAT — · OPM change -33.8 pp 39% evidence | 3.6/25 ROCE -2.4% · OPM -25.3% 76% evidence | 8.8/20 P/E 69.4× · PEG — 15% evidence | 10.5/20 RS sector 6% · RS bench 3.1% · 1Y 82.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 3.6 + 8.8 + 10.5 = 35 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Matador Resources CompanyMTDR | 31.2/100Adverse evidence81% evidence | BASING | 9.4/35 Revenue -2.9% · PAT -42.9% · OPM change -33.7 pp 83% evidence | 8.3/25 ROCE 0.5% · OPM 5% 76% evidence | 10.3/20 P/E 16.2× · PEG 0.9 65% evidence | 3.2/20 RS sector -9.3% · RS bench -11.4% · 1Y 4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 8.3 + 10.3 + 3.2 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29California Resources CorporationCRC | 21.8/100Adverse evidence71% evidence | BASING | 4.1/35 Revenue -21.3% · PAT -192.4% · OPM change -617.9 pp 83% evidence | 4.7/25 ROCE -12.3% · OPM -597.5% 76% evidence | 10.6/20 P/E 10.8× · PEG — 15% evidence | 2.4/20 RS sector -11.2% · RS bench -13.2% · 1Y 10.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 4.1 + 4.7 + 10.6 + 2.4 = 21.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Woodside Energy Group LtdWDS | 53.4/100Thin evidence · provisional32% evidence | ASLEEP | 17.6/35 Revenue — · PAT — · OPM change — 9% evidence | 10.8/25 ROCE 1.8% · OPM — 46% evidence | 10.5/20 P/E 11× · PEG — 15% evidence | 14.5/20 RS sector 8.5% · RS bench 5.7% · 1Y 28.7%1 of 12 weeks ahead 70% evidence |
| Exact sum: 17.6 + 10.8 + 10.5 + 14.5 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Ovintiv Inc.'s stock price today?
Ovintiv Inc. trades at $60.8, +54.1% over the past year. The company is valued at $17.0 B. The stock sits at 91% of its 52-week range of $36–$63, +22.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 23 weeks in. — as of 5 August 2026.
What were Ovintiv Inc.'s latest quarterly results?
Ovintiv Inc. reported revenue of $2.6 B and a net loss of $0.6 B for the Mar 26 quarter. Earnings per share were $−2.35. The operating margin was 29.1%, 1.8 pp higher than a year earlier. — as of 5 August 2026.
What is Ovintiv Inc.'s revenue?
Ovintiv Inc. reported revenue of $2.6 B in the Mar 26 quarter, +8.4% year on year. For the full FY25 fiscal year, revenue was $8.7 B (−3.1%). Over the last 4 years revenue compounded at −4.6% a year. — as of 5 August 2026.
What is Ovintiv Inc.'s profit?
Ovintiv Inc. earned $−0.6 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $1.2 B. The operating margin ran 29.1% in the latest quarter. — as of 5 August 2026.
What is Ovintiv Inc.'s market cap?
Ovintiv Inc.'s market capitalisation is $17.0 B at a stock price of $60.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Ovintiv Inc. pay a dividend?
Yes — Ovintiv Inc. declared $0.30 per share for Mar 26, and $1.20 per share across the last four reported quarters. The latest quarter is up 20.0% on the same quarter a year earlier. — as of 5 August 2026.
What is Ovintiv Inc.'s dividend per share?
Ovintiv Inc.'s most recently declared dividend is $0.30 per share for Mar 26, giving $1.20 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Ovintiv Inc.'s dividend yield?
Ovintiv Inc.'s trailing dividend yield is 1.98%: $1.20 declared per share across the last four reported quarters, against a share price of $60.8. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
How is Ovintiv Inc. performing?
Ovintiv Inc. is in a confirmed uptrend, 23 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Ovintiv Inc. in?
Turning around — profit growth swung from −69.2% at the trough to +23.8%, a 2-quarter improving streak, ROCE holding at 12.2%. The read comes from the last 12 quarters of growth (revenue growth −0.9% latest, profit growth +23.8% latest, eps growth +31.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Ovintiv Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 23 of stage 2), trading +22.4% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Ovintiv Inc. beating the market?
On recent form, yes — Ovintiv Inc. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +59% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Ovintiv Inc.'s stock price go up?
This page publishes no price forecast for Ovintiv Inc. What it measures instead: the stock price is $60.8, the price is in a confirmed uptrend 23 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Ovintiv Inc.?
Somewhat — short interest is 5.2% of Ovintiv Inc.'s tradable float, about 4.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Ovintiv Inc. have too much debt?
It is moderate — Ovintiv Inc.'s debt-to-equity is 0.44. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Ovintiv Inc.'s capex?
Ovintiv Inc. spent $10.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $4.7 B. — as of 5 August 2026.
What is Ovintiv Inc.'s cash flow?
Ovintiv Inc. generated $3.6 B of operating cash flow in FY25 and $−1.0 B of free cash flow after $4.7 B of capital spending. Reported profit that year was $1.2 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Ovintiv Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 259% of Ovintiv Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $3.6 B against reported profit of $1.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Ovintiv Inc.?
On the balance sheet, the Z-score reads 2.06 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is Ovintiv Inc. in its business cycle?
Ovintiv Inc.'s FY25 operating margin was 23.9%, against a 5-year band of 14.6%–27.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 29.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Ovintiv Inc. story?
The sharpest disagreement: the price moved +54.1% in a year while annual EPS moved +13.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Ovintiv Inc. a stock worth studying right now?
This is not investment advice. The machine read: Ovintiv Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.